CDMO Avid Bioservices

Avid Bioservices Receives Five 2020 CMO Leadership Awards

Avid Bioservices Receives Five 2020 CMO Leadership Awards

Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry

Named 2020 CMO Leadership Award Champion in Categories of Expertise and Service

TUSTIN, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has been named a recipient of five 2020 Contract Manufacturing Organization (CMO) Leadership Awards.  Presented by the industry publication Life Science Leader and based on market research and surveys conducted by Industry Standard Research (ISR), these awards are intended to honor those companies in the contract manufacturing space that provide their customers with the industry’s highest level of service. 

Avid received awards in the following categories:

  • Capabilities
  • Expertise
  • Reliability
  • Compatibility
  • Service

Additionally, the company was named a 2020 CMO Leadership Award Champion in the categories of expertise and service.  Top performing companies are recognized as Champions if they scored a one-half standard deviation or more above the weighted average in a specific category.

“Avid is honored to be recognized by the CMO Leadership Awards, particularly by our designation as a Champion in the expertise and service categories.  The CMO Leadership Awards are among the most meaningful in our industry as the winners are selected, in part, based on feedback from CDMO industry customers.  As a company whose entire business philosophy is built upon the concept of doing whatever it takes to deliver for our customers, this recognition is truly gratifying,” said Rick Hancock, interim president and chief executive officer of Avid.  “The excellence required to be recognized by our customers and the broader CDMO industry is a collective effort and we thank each and every member of the Avid team for their important contributions to the company’s success.”   

Life Science Leader’s CMO Leadership Awards aim to provide industry insiders with accurate and reliable customer feedback to assist them in choosing a reputable partner for their development and manufacturing needs. For more information about Life Science Leader’s CMO Leadership Awards, please visit: .

About Avid Bioservices, Inc.

Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. 

Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
 

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
 
EN
26/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avid Bioservices

 PRESS RELEASE

Avid Bioservices Reports Financial Results for Third Quarter Ended Jan...

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 -- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion Program with Grand Opening of Cell and Gene Therapy Manufacturing Facility in January 2024 -- -- Completed Convertible Debt Offering Subsequent to Quarter End, Extending Debt Maturity to 2029 -- TUSTIN, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contra...

 PRESS RELEASE

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Re...

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “Notice”) on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to ...

 PRESS RELEASE

Avid Bioservices Announces Pricing of Private Placement of Convertible...

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). In connection with the offering, the company entered into private placement purchase agreements with the several purchasers, each of whom is a “qualified institutional buyer” within the meaning of Rule 144A promul...

 PRESS RELEASE

Avid Bioservices Announces Proposed Private Placement of Convertible N...

Avid Bioservices Announces Proposed Private Placement of Convertible Notes TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 (the “2029 Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act of 19...

 PRESS RELEASE

Avid Bioservices Announces Certain Preliminary Financial Results for T...

Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024. The company expects results in the third quarter of fiscal 2024 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch